Search the Newsreel

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

Bristol-Myers Squibb Company supera las previsiones de los analistas: descubre cuáles son las previsiones de consenso para este año

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Bristol-Myers Squibb Company : Consenso de Precios Objetivo y Recomendaciones de los Analistas | BMY | US1101221083

Guggenheim eleva el precio objetivo de Bristol-Myers Squibb a 75 dólares

Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus

Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Bristol-Myers Squibb superaron 0.43$ las previsiones de BPA en el segundo trimestre del año

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

Bristol Myers Lifts Outlook as Profit, Revenue Rise

Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol-Myers Squibb (NYSE:BMY) reported strong Q2 CY2026 financial results, surpassing analyst expectations for both revenue and non-GAAP profit. The company's revenue grew 5.7% year-on-year to $12.97 billion, and its full-year revenue guidance of $49.5 billion also exceeded estimates. Despite strong quarterly performance, the company …

Edgestream Partners L.P. Buys Shares of 154,427 Bristol Myers Squibb Company $BMY

Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …

Informe de resultados: Bristol Myers supera las estimaciones del segundo trimestre de 2026

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

¿Han cambiado la presentación conjunta de la solicitud de Opdivo y la expansión de la I+D impulsada por la IA el enfoque de inversión de Bristol-Myers Squibb (BMY)?

The Manufacturers Life Insurance Company Raises Stock Holdings in Bristol Myers Squibb Company $BMY

The Manufacturers Life Insurance Company increased its holdings in Bristol Myers Squibb (NYSE:BMY) by 15.8% in the first quarter, adding 241,405 shares to reach a total value of approximately $107.1 million. Institutional investors now own 76.41% of BMY, while analyst sentiment remains mixed with …

Opal Capital LLC Buys Shares of 22,664 Bristol Myers Squibb Company $BMY

Opal Capital LLC recently acquired 22,664 shares of Bristol Myers Squibb (NYSE:BMY) in the first quarter, valued at approximately $1,375,000. Other institutional investors have also adjusted their holdings in the biopharmaceutical company, which has seen its stock perform within a 12-month range of $42.52 …

BMY|Bristol-Myers Squibb Co|Price:63.635|Chg%:+1.075

This article provides a comprehensive overview of Bristol-Myers Squibb Co (BMY) stock, including real-time quotes, key financial figures, performance trends, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The stock is currently rated …

California State Teachers Retirement System Has $201.19 Million Stake in Bristol Myers Squibb Company $BMY

The California State Teachers Retirement System reduced its stake in Bristol Myers Squibb Company (BMY) by 2.3% in the first quarter, now owning 3,317,201 shares valued at $201.19 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts currently rate …